Third Rock Ventures LLC, a venture capital firm, announced the formation of MyoKardia Inc. with a $38 million Series A financing of the company. MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease. Christine Seidman, Thomas W. Smith Professor of Medicine at Brigham and Women's Hospital and Jonathan Seidman, Henrietta B. and Frederick H. Bugher Foundation Professor of Genetics at HMS, are mentioned as cofounders of the company.
News & Research
